IL6 and cancer: Currently available data suggests some innovative therapies aimed to reduce mortality in patients with STEMI and SARS-CoV-2 infection, including selective inhibitors of interleukin 1 or interleukin 6, especially in vulnerable patients, such as those with cancer.